The first pretreated patient with HER2-altered non–small cell lung cancer was dosed with NVL-330, a novel HER2-selective ...

As AstraZeneca and Astex's capivasertib gains market presence in breast cancer, could it be the time for AKT inhibitors?

CDK4/6 inhibitors are targeted drugs that can be used for women with a common type of breast cancer: hormone ...

NVL-330 is a novel brain-penetrant HER2-selective tyrosine kinase inhibitor designed to address the combined medical need of treating HER2-altered tumors, including those with HER2 exon 20 ...

Erika Hamilton, MD, discussed findings from the phase 1b/2 ELECTRA study investigating a new oral combination therapy for ...

Targeted medicines are drugs that target the HER2 protein. There are different types of targeted therapies, including monoclonal antibodies, antibody-drug conjugates, and kinase inhibitors.

A new study from the University of Michigan Health Rogel Cancer Center finds that giving a fatty acid inhibitor alongside chemotherapy could improve the treatment efficacy for patients with brain ...

The firm reported $845 million in Q2 revenue from oncology products gained in its acquisition of Seagen last year.

its Phase 1a/1b clinical trial evaluating its novel HER2-selective inhibitor, NVL-330, for pre-treated patients with HER2-altered non-small cell lung cancer (NSCLC). "HER2 alterations are an ...

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the ...